Skip navigation

Addressing the Reimbursement and Regulatory Challenges of Pharmacological Solutions to the Opioid Epidemic

December 7, 2017
  • Philadelphia, PA

CBI’s Abuse Deterrent Formulations Critical Update serves as the only 1-day event designed for executives who want a deep dive into the latest developments in state legislation, regulatory expectations and commercialization strategies for ADF labeled opioids. Senior-level executives will discuss their experiences and outcomes negotiating reimbursement with health plans, obtaining clarity about the latest FDA requirements, data supporting the efficacy of ADF opioids and differing state and federal policies effecting the use and manufacturing of ADF labeled drugs.

Topics and Interactive DiscussionS Include:

  • FDA Regulations
  • ICER Results and How to Best Address Them
  • How to Address Increasing State Regulations
    When Payers Don’t Want to Pay
  • Leveling the Playing Field Between ADF and Regular Opioids
  • Tracking the Various State Regulations

Previous Attendee Acclaim:

ADF technology is new and evolving. Large, post-marketing studies comparing specific products with conventional opioids are starting to be published and indicate that nonmedical use is lower with ADFs.”

Abuse-Deterrent Formulations: One Tool in the Opioid-Abuse Epidemic, Pharmacy Times, August 30, 2017

Given the complexity of the task at hand, it is clear that innovation in the area of abuse-deterrent formulations, delivery systems, pro-drugs and new chemical entities alone will not be able to solve the issue in full. However, the aforementioned innovations play a vital role and can contribute to reaching the overall aim of reducing the abuse of prescription medicines.

Innovative Abuse-Deterrent Opioid Medications, American Pharmaceutical Review, January 31, 2016

Abuse Deterrent Formulations Critical Update

Addressing the Reimbursement and Regulatory Challenges of Pharmacological Solutions to the Opioid Epidemic

CBI’s Abuse Deterrent Formulations Critical Update serves as the only 1-day event designed for executives who want a deep dive into the latest developments in state legislation, regulatory expectations and commercialization strategies for ADF labeled opioids. Senior-level executives will discuss their experiences and outcomes negotiating reimbursement with health plans, obtaining clarity about the latest FDA requirements, data supporting the efficacy of ADF opioids and differing state and federal policies effecting the use and manufacturing of ADF labeled drugs.

Topics and Interactive DiscussionS Include:

  • FDA Regulations
  • ICER Results and How to Best Address Them
  • How to Address Increasing State Regulations
    When Payers Don’t Want to Pay
  • Leveling the Playing Field Between ADF and Regular Opioids
  • Tracking the Various State Regulations

Previous Attendee Acclaim:

ADF technology is new and evolving. Large, post-marketing studies comparing specific products with conventional opioids are starting to be published and indicate that nonmedical use is lower with ADFs.”

Abuse-Deterrent Formulations: One Tool in the Opioid-Abuse Epidemic, Pharmacy Times, August 30, 2017

Given the complexity of the task at hand, it is clear that innovation in the area of abuse-deterrent formulations, delivery systems, pro-drugs and new chemical entities alone will not be able to solve the issue in full. However, the aforementioned innovations play a vital role and can contribute to reaching the overall aim of reducing the abuse of prescription medicines.

Innovative Abuse-Deterrent Opioid Medications, American Pharmaceutical Review, January 31, 2016